Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

Xiaohui Liu(Brigham and Women's Hospital), Jennifer L. Ide(Brigham and Women's Hospital), Isaiah Norton(Harvard University), Mark A. Marchionni(Harvard University), Maritza Ebling(Harvard University), Lan Y Wang(Dana-Farber Cancer Institute), Erin Davis(Harvard University), Claire Sauvageot(Dana-Farber Cancer Institute), Santosh Kesari(University of California, San Diego), Katherine A. Kellersberger(Bruker (United States)), Michael L. Easterling(Bruker (United States)), Sandro Santagata(Brigham and Women's Hospital), Darrin D. Stuart(Novartis (United States)), John A. Alberta(Dana-Farber Cancer Institute), Jeffrey N. Agar(Brandeis University), Charles D. Stiles(Harvard University), Nathalie Y.R. Agar(Harvard University)
Scientific Reports
October 4, 2013
Cited by 131Open Access
Full Text

Abstract

Drug transit through the blood-brain barrier (BBB) is essential for therapeutic responses in malignant glioma. Conventional methods for assessment of BBB penetrance require synthesis of isotopically labeled drug derivatives. Here, we report a new methodology using matrix assisted laser desorption ionization mass spectrometry imaging (MALDI MSI) to visualize drug penetration in brain tissue without molecular labeling. In studies summarized here, we first validate heme as a simple and robust MALDI MSI marker for the lumen of blood vessels in the brain. We go on to provide three examples of how MALDI MSI can provide chemical and biological insights into BBB penetrance and metabolism of small molecule signal transduction inhibitors in the brain - insights that would be difficult or impossible to extract by use of radiolabeled compounds.


Related Papers

No related papers found

Powered by citation graph analysis